Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DMAC Stock Forecast 2026-2027
$7.13
Current Price
$411.67M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DMAC Price Targets
+250.6%
To High Target of $25.00
+82.3%
To Median Target of $13.00
+54.3%
To Low Target of $11.00
DMAC Price Momentum
-7.0%
1 Week Change
+24.4%
1 Month Change
+81.4%
1 Year Change
-10.4%
Year-to-Date Change
-31.6%
From 52W High of $10.42
+95.3%
From 52W Low of $3.65
📊 TOP ANALYST CALLS
Did DMAC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if DiaMedica is one of their latest high-conviction picks.
Latest DMAC Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, DMAC has a bullish consensus with a median price target of $13.00 (ranging from $11.00 to $25.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $7.13, the median forecast implies a 82.3% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Josh Schimmer at Cantor Fitzgerald, projecting a 250.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DMAC Analyst Ratings
5
Buy
0
Hold
0
Sell
DMAC Price Target Range
Low
$11.00
Average
$13.00
High
$25.00
Current: $7.13
Latest DMAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DMAC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2025 | Cantor Fitzgerald | Josh Schimmer | Overweight | Initiates | $25.00 |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 18, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| Jul 18, 2025 | Lake Street | Buy | Maintains | $N/A | |
| Jul 18, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 29, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 19, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 10, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 7, 2024 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Aug 16, 2024 | Oppenheimer | Outperform | Reiterates | $N/A | |
| Apr 24, 2024 | Craig-Hallum | Alexander Nowak | Buy | Assumes | $8.00 |
| Mar 21, 2024 | Craig-Hallum | Buy | Maintains | $N/A | |
| Mar 21, 2024 | Oppenheimer | Outperform | Reiterates | $N/A | |
| Jun 22, 2023 | Oppenheimer | Outperform | Upgrade | $N/A | |
| Jul 7, 2022 | Lake Street | Buy | Maintains | $N/A | |
| Jul 7, 2022 | Craig-Hallum | Buy | Maintains | $N/A | |
| Jul 7, 2022 | Oppenheimer | Perform | Downgrade | $N/A | |
| Jun 30, 2021 | Roth Capital | Buy | Maintains | $N/A | |
| Apr 9, 2021 | Oppenheimer | Outperform | Initiates | $N/A |
DiaMedica Therapeutics Inc. (DMAC) Competitors
The following stocks are similar to DiaMedica based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DiaMedica Therapeutics Inc. (DMAC) Financial Data
DiaMedica Therapeutics Inc. has a market capitalization of $411.67M with a P/E ratio of -10.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -86.5%.
Valuation Metrics
Market Cap
$411.67M
Enterprise Value
$352.47M
P/E Ratio
-10.9x
PEG Ratio
-2.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+13.4%
Current Ratio
9.1x
Debt/Equity
0.4x
ROE
-86.5%
ROA
-50.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
DiaMedica Therapeutics Inc. (DMAC) Business Model
About DiaMedica Therapeutics Inc.
What They Do
Develops therapies for vascular diseases.
Business Model
The company operates as a clinical-stage biopharmaceutical firm, focusing on developing innovative therapies for serious vascular conditions. It generates revenue through the advancement of its lead candidate, DM199, which is aimed at enhancing blood flow and vascular health, targeting conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke, as well as exploring opportunities in chronic kidney disease.
Additional Information
Founded in 2000 and based in Minneapolis, Minnesota, DiaMedica Therapeutics engages in clinical development and regulatory interactions to address significant unmet medical needs in vascular health. The company is currently involved in several clinical trials, including Phase 2 and Phase 2/3 studies, to validate its treatment approaches.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
35
CEO
Mr. Dietrich John Pauls MBA
Country
United States
IPO Year
2018
Website
www.diamedica.comDiaMedica Therapeutics Inc. (DMAC) Latest News & Analysis
Latest News
Quick Summary
DiaMedica Therapeutics Inc. has begun dosing patients in a Phase 2 trial for DM199, evaluating its effectiveness in treating fetal growth restriction. This marks the drug's first clinical assessment in this area.
Why It Matters
Dosing of the first patients in a Phase 2 trial for DM199 signals progress in DiaMedica's drug development, potentially enhancing its market value and attracting investor interest in the biopharmaceutical sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
DiaMedica Therapeutics (Nasdaq: DMAC) received FDA feedback requesting more nonclinical reproductive toxicity data for DM199 (rinvecalinase alfa) in preeclampsia treatment, which may affect its development timeline.
Why It Matters
FDA's request for more reproductive toxicity data on DM199 affects its development timeline and regulatory approval, impacting investor sentiment and potential market value for DiaMedica.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026, at 3:45 PM ET, focusing on its biopharmaceutical developments.
Why It Matters
DiaMedica's presentation at a major healthcare conference highlights its focus on novel treatments, which could attract investor interest and influence stock performance.
Source: Business Wire
Market Sentiment:
Neutral
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
1 month ago
Quick Summary
DiaMedica Therapeutics reports 75% enrollment in the pivotal Phase 2/3 ReMEDy2 trial for DM199 in acute ischemic stroke, nearing the 200-patient threshold for an interim analysis.
Why It Matters
The advancement in DiaMedica's clinical trial can boost investor confidence, potentially leading to stock price appreciation as the company nears critical trial milestones.
Source: Business Wire
Market Sentiment:
Neutral
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
2 months ago
Quick Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) CEO Rick Pauls will speak at the RBC Capital Markets Global Healthcare Conference on May 19, 2026, from 4:05-4:30 PM in New York City.
Why It Matters
DiaMedica's participation in the RBC Global Healthcare Conference highlights its focus on critical health issues, potentially attracting investor interest and influencing stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
DiaMedica Therapeutics Inc. (DMAC) held its Q1 2026 earnings call, providing updates on financial performance and strategic initiatives. Further details on earnings and projections were discussed.
Why It Matters
DiaMedica Therapeutics' Q1 2026 earnings call provides insights into financial performance, strategic direction, and future growth potential, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About DMAC Stock
What is DiaMedica Therapeutics Inc.'s (DMAC) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, DiaMedica Therapeutics Inc. (DMAC) has a median price target of $13.00. The highest price target is $25.00 and the lowest is $11.00.
Is DMAC stock a good investment in 2027?
According to current analyst ratings, DMAC has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DMAC stock?
Wall Street analysts predict DMAC stock could reach $13.00 in the next 12 months. This represents a 82.3% increase from the current price of $7.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is DiaMedica Therapeutics Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical firm, focusing on developing innovative therapies for serious vascular conditions. It generates revenue through the advancement of its lead candidate, DM199, which is aimed at enhancing blood flow and vascular health, targeting conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke, as well as exploring opportunities in chronic kidney disease.
What is the highest forecasted price for DMAC DiaMedica Therapeutics Inc.?
The highest price target for DMAC is $25.00 from Josh Schimmer at Cantor Fitzgerald, which represents a 250.6% increase from the current price of $7.13.
What is the lowest forecasted price for DMAC DiaMedica Therapeutics Inc.?
The lowest price target for DMAC is $11.00 from at , which represents a 54.3% increase from the current price of $7.13.
What is the overall DMAC consensus from analysts for DiaMedica Therapeutics Inc.?
The overall analyst consensus for DMAC is bullish. Out of 3 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are DMAC stock price projections?
Stock price projections, including those for DiaMedica Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:25 AM UTC